Vitamin D analogs: New therapeutic agents for secondary hyperparathyroidism

Keyphrases

• New Therapeutic Agents 100%
• Parathyroid Glands 100%
• Secondary Hyperparathyroidism 100%
• Vitamin D Analogs 100%
• Chronic Kidney Disease 66%
• 1,25(OH)2D3 66%
• Calcitriol 66%
• Calcemic Effect 66%
• Maxacalcitol 66%
• Gene Expression 33%
• Coronary Artery Disease 33%
• Phosphate 33%
• Japan 33%
• Replacement Therapy 33%
• Low Serum 33%
• Intact Parathyroid Hormone (iPTH) 33%
• Renal Transplant Recipients 33%
• Bone Resorption 33%
• Most Common Cause 33%
• Effective Means 33%
• Vascular Calcification 33%
• Distinct Mechanism 33%
• Hyperphosphatemia 33%
• Causes of Mortality 33%
• Hypercalcemia 33%
• Reabsorption 33%
• Phosphate Retention 33%
• Hormone-related Genes 33%
• Sustained Effect 33%
• NOR1 33%
• Rapid Clearance 33%
• Intestinal Calcium Absorption 33%
• Calcium-based Phosphate Binders 33%
• Vitamin D Compounds 33%
• Falecalcitriol 33%
• Alfacalcidol 33%
• Paricalcitol 33%
• Synthetic Precursor 33%
• Doxercalciferol 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Secondary Hyperparathyroidism 100%
• Vitamin D Analog 100%
• Calcitriol 66%
• Chronic Kidney Failure 66%
• 22 Oxacalcitriol 66%
• Replacement Therapy 33%
• Vitamin D 33%
• Coronary Artery Disease 33%
• Parathyroid Hormone 33%
• Hyperphosphatemia 33%
• Blood Vessel Calcification 33%
• Hypercalcaemia 33%
• Phosphate Binding Agent 33%
• 2 Methyl 5 Trimethylammoniomethyl 1,3 Oxathiolane 33%
• Alfacalcidol 33%
• Falecalcitriol 33%
• Paricalcitol 33%
• Doxercalciferol 33%

Biochemistry, Genetics and Molecular Biology

• Calcitriol 100%
• Vitamin D Analog 100%
• Gene Expression 50%
• Vitamin D 50%
• Precursor 50%
• Parathyroid Hormone 50%
• Osteolysis 50%
• Hypercalcaemia 50%
• Calcium Absorption 50%
• Alfacalcidol 50%
• Paricalcitol 50%
• Doxercalciferol 50%